CS
CGON icon

Candriam SCA’s CG Oncology CGON Stock Holding History

Candriam SCA’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.7M Sell
542,036
-255,579
-32% -$14.5M 0.19% 120
2025
Q4 		$33.1M Sell
797,615
-240,277
-23% -$9.94M 0.17% 134
2025
Q3 		$41.8M Buy
1,037,892
+274,312
+36% +$7.97M 0.22% 103
2025
Q2 		$19.9M Buy
+763,580
New +$18.4M 0.11% 167

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Candriam SCA's CGON Position: Q1 2026 in Review

Candriam SCA reduced its CG Oncology (CGON) stake by 32% in Q1 2026, selling an estimated $14.5M and leaving 542,036 shares worth $36.7M. The position accounts for 0.19% of the portfolio, ranked #120.

Candriam SCA first reported a position in CGON in Q2 2025 and has held it in 4 quarters since. The position peaked at $41.8M in Q3 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Candriam SCA held 542,036 shares of CG Oncology worth $36.7M as of Q1 2026.
  • Candriam SCA sold 255,579 CG Oncology shares in Q1 2026, an estimated $14.5M.
  • CG Oncology made up 0.19% of Candriam SCA's portfolio in Q1 2026, its #120 holding.
  • Candriam SCA first reported a position in CG Oncology in Q2 2025 and has held it in 4 quarters since.
  • Candriam SCA's CG Oncology position peaked at $41.8M in Q3 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.